Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Aberrant expression of glycoconjugates occurs during malignant transformation of cancer cells. Overexpression of sialoglycoconjugates in particular may play an important role in the progression, i.e., invasion or metastasis, of cancer. Various types of sialoglycoconjugates have been investigated to clarify their biological significance and clinical utility in diagnosing and treating colorectal cancer. This review focuses specifically on expression of mucin (MUC) 1 and it suggests that MUC1 with the specific structure of a sialo-oligosaccharide has biological significance in determining the metastatic potential of colorectal cancer cells and clinicopathological utility in evaluating the effectiveness of treatments and the prognosis for patients with colorectal cancer. Further studies are expected to contribute to the expanded use of cancer-associated sialoglycoconjugates in cancer diagnosis and therapy.

[1]  Y. Ueda,et al.  Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. , 2013, World journal of gastroenterology.

[2]  S. Yamashita,et al.  Clinicopathological subclassification of biliary cystic tumors: Report of 4 cases with a review of the literature. , 2013, Intractable & rare diseases research.

[3]  Y. Collan,et al.  Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma , 2013, Tumor Biology.

[4]  Wei Tang,et al.  Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. , 2013, Bioscience trends.

[5]  H. Nakada,et al.  Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor, on the growth of colon cancer cells. , 2012, Bioscience trends.

[6]  Yuemao Shen,et al.  Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. , 2012, Drug discoveries & therapeutics.

[7]  Jianjun Gao,et al.  Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. , 2012, Bioscience trends.

[8]  P. Song,et al.  "Knowledge into action" Exploration of an appropriate approach for constructing evidence-based clinical practice guidelines for hepatocellular carcinoma. , 2012, Bioscience trends.

[9]  Minyoung Lee,et al.  Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. , 2012, Biochemical pharmacology.

[10]  Minyoung Lee,et al.  Cleavage of ST6Gal I by Radiation-Induced BACE1 Inhibits Golgi-Anchored ST6Gal I-Mediated Sialylation of Integrin β1 and Migration in Colon Cancer Cells , 2012, Radiation oncology.

[11]  K. Yamashita,et al.  Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody. , 2012, Glycobiology.

[12]  G. Francini,et al.  CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab , 2012, Cancer investigation.

[13]  E. Cuevas,et al.  sLea and sLex expression in colorectal cancer: implications for tumourigenesis and disease prognosis. , 2011, Histology and histopathology.

[14]  S. Bellis,et al.  Sialylation of the Fas Death Receptor by ST6Gal-I Provides Protection against Fas-mediated Apoptosis in Colon Carcinoma Cells* , 2011, The Journal of Biological Chemistry.

[15]  Jianjun Gao,et al.  Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. , 2011, Bioscience trends.

[16]  Hoguen Kim,et al.  Loss of E-cadherin and MUC2 Expressions Correlated with Poor Survival in Patients with Stages II and III Colorectal Carcinoma , 2011, Annals of Surgical Oncology.

[17]  Y. Inagaki,et al.  c-Met: A potential therapeutic target for hepatocellular carcinoma. , 2011, Drug discoveries & therapeutics.

[18]  Upender Manne,et al.  Prognostic value of mucin 4 expression in colorectal adenocarcinomas , 2010, Cancer.

[19]  M. Ducreux,et al.  Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[20]  S. Nishimura,et al.  An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. , 2009, Journal of the American Chemical Society.

[21]  A. Takayanagi,et al.  Isolation and characterization of anti-T-antigen single chain antibodies from a phage library. , 2009, Bioscience trends.

[22]  M. Makuuchi,et al.  KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. , 2009, Hepato-Gastroenterology.

[23]  Y. Zhuo,et al.  Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms. , 2008, Experimental cell research.

[24]  D. Santini,et al.  Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon. , 2007, Glycobiology.

[25]  M. Makuuchi,et al.  Subcellular localization of KL-6 mucin in colorectal carcinoma cell lines: association with metastatic potential and cell morphology. , 2007, Oncology reports.

[26]  M. Grimm,et al.  Comparative Analysis of Predictive Biomarkers for Therapeutical Strategies in Colorectal Cancer , 2007, Annals of Surgical Oncology.

[27]  M. Makuuchi,et al.  Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. , 2006, World journal of gastroenterology.

[28]  C. Vázquez‐Martín,et al.  Elevation of ST6Gal I Activity in Malignant and Transitional Tissue in Human Colorectal Cancer , 2005, Oncology.

[29]  J. Wakefield,et al.  Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. , 2005, Cancer research.

[30]  J. Kihlberg,et al.  Role of the Human ST6GalNAc-I and ST6GalNAc-II in the Synthesis of the Cancer-Associated Sialyl-Tn Antigen , 2004, Cancer Research.

[31]  C. Vázquez‐Martín,et al.  Correlation Analysis between Tumorous Associated Antigen Sialyl-Tn Expression and ST6GalNAc I Activity in Human Colon Adenocarcinoma , 2004, Oncology.

[32]  K. Kumamoto,et al.  Loss of Disialyl Lewisa, the Ligand for Lymphocyte Inhibitory Receptor Sialic Acid-Binding Immunoglobulin-Like Lectin-7 (Siglec-7) Associated with Increased Sialyl Lewisa Expression on Human Colon Cancers , 2004, Cancer Research.

[33]  T. Ando,et al.  Synthesis of Disialyl Lewis a (Lea) Structure in Colon Cancer Cell Lines by a Sialyltransferase, ST6GalNAc VI, Responsible for the Synthesis of α-Series Gangliosides* , 2003, Journal of Biological Chemistry.

[34]  K. Arisawa,et al.  Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. , 2003, Hepato-gastroenterology.

[35]  T. Irimura,et al.  The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. , 2002, Journal of immunological methods.

[36]  R. Kannagi Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. , 2002, Current opinion in structural biology.

[37]  P. Kirkham,et al.  Mapping of two new epitopes on the apomucin encoded by MUC5AC gene: Expression in normal GI tract and colon tumors , 2002, International journal of cancer.

[38]  A. Hölscher,et al.  Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.

[39]  Kan Yang,et al.  Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2 , 2002, Science.

[40]  I. van Seuningen,et al.  Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer? , 2001, Frontiers in bioscience : a journal and virtual library.

[41]  R. Goodlad,et al.  Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. , 2001, Glycobiology.

[42]  A. Nanashima,et al.  Circulating sialyl Lewisx, sialyl Lewisa, and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels , 2001, Journal of Gastroenterology.

[43]  W. Hohenberger,et al.  CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  O. Topolcan,et al.  The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. , 2000, Anticancer research.

[45]  D. Santini,et al.  β‐galactoside α2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with sambucus nigra agglutinin , 2000, International journal of cancer.

[46]  H. Weiss,et al.  Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  T. Hamamoto,et al.  Redefined substrate specificity of ST6GalNAc II: a second candidate sialyl-Tn synthase. , 2000, Biochemical and biophysical research communications.

[48]  M. Páez de la Cadena,et al.  Immunohistochemical Analysis of Sialic Acid and Fucose Composition in Human Colorectal Adenocarcinoma , 2000, Tumor Biology.

[49]  N. Kohno,et al.  Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. , 1999, The journal of medical investigation : JMI.

[50]  S. Nordling,et al.  Sialyl Tn Is a Frequently Expressed Antigen in Colorectal Cancer: No Correlation with Patient Prognosis , 1999, Oncology.

[51]  M. Tanaka,et al.  CEA and CA 19-9 as prognostic indexes in colorectal cancer. , 1999, Hepato-gastroenterology.

[52]  G. Niehans,et al.  Aberrant expression of MUC5AC and MUC6 gastric mucin genes in colorectal polyps , 1999, International journal of cancer.

[53]  N. Kohno,et al.  Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal Cancer , 1998, Oncology.

[54]  S. Baldus,et al.  Coexpression of MUC1 mucin peptide core and the thomsen‐friedenreich antigen in colorectal neoplasms , 1998, Cancer.

[55]  H. Stein,et al.  MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[56]  A. Cailleux,et al.  Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer. , 1997, European journal of cancer.

[57]  M. Kitajima,et al.  Prognostic values of serum CA19-9 and CEA levels for colorectal cancer. , 1997, Oncology Report.

[58]  R. Kannagi,et al.  Altered mRNA expression of specific molecular species of fucosyl‐ and sialyl‐transferases in human colorectal cancer tissues , 1997, International journal of cancer.

[59]  C. Stanners,et al.  Cell-surface levels of human carcinoembryonic antigen are inversely correlated with colonocyte differentiation in colon carcinogenesis. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[60]  M. Páez de la Cadena,et al.  Sialic acid levels in serum and tissue from colorectal cancer patients. , 1997, Cancer letters.

[61]  S. Hakomori Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.

[62]  M. Hanski,et al.  Fucosyltransferase III and sialyl-Lex expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue , 1996, Glycoconjugate Journal.

[63]  Y. Kim,et al.  Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. , 1996, Gastroenterology.

[64]  T. Irimura,et al.  A Novel Monoclonal Antibody Specific for Sialylated MUC1 Mucin , 1996, Japanese journal of cancer research : Gann.

[65]  K. Krause,et al.  Quantitative lectinhistochemical and immunohistochemical studies on the occurrence of alpha(2,3)‐ and alpha(2,6)‐linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features , 1995, Cancer.

[66]  S. Oikawa,et al.  Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encoding carcinoembryonic antigen , 1994, Clinical & Experimental Metastasis.

[67]  S. Kamihira,et al.  An immunohistochemical employer monoclonal antibodies against Lea, sialyl Lea, Lex, and sialyl Lex antigens in primary colorectal, carcinomas and lymph node and hepatic lesions , 1994, Journal of Gastroenterology.

[68]  S. Kamihira,et al.  Immunohistochemical expression of sialyl lex antigen in relation to survival of patients with colorectal carcinoma , 1993, Cancer.

[69]  T. Irimura,et al.  Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. , 1993, Cancer research.

[70]  T. Irimura,et al.  Regulation of sialomucin production in colon carcinoma cells. , 1993, The Journal of biological chemistry.

[71]  R. Kannagi,et al.  Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. , 1993, Cancer research.

[72]  D. Milne,et al.  Membranous expression of carcinoembryonic antigen (CEA) in the normal cervical squamous mucosa , 1992, The Journal of pathology.

[73]  Judith P. Johnson Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease , 1991, Cancer and Metastasis Reviews.

[74]  S. Hakomori,et al.  Sialosyl‐Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients , 1990, Cancer.

[75]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[76]  J. Taylor‐Papadimitriou,et al.  A short sequence, within the amino acid tandem repeat of a cancer‐associated mucin, contains immunodominant epitopes , 1989, International journal of cancer.

[77]  N. Kohno,et al.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.

[78]  I. Goldstein,et al.  The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. , 1987, The Journal of biological chemistry.

[79]  N. Zamcheck,et al.  Effect of heterogeneity of carcinoembryonic antigen on liver cell membrane binding and its kinetics of removal from circulation. , 1985, Cancer research.

[80]  W. Bodmer,et al.  Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.

[81]  P. Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.

[82]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[83]  Aung Ko Win,et al.  Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype , 2013, Modern Pathology.

[84]  A. Goel,et al.  Association of p53 codon 248 (exon7) with urinary bladder cancer risk in the North Indian population. , 2011, Bioscience trends.

[85]  J. Taylor‐Papadimitriou,et al.  ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. , 2011, Frontiers in bioscience.

[86]  K. Mizokami,et al.  First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. , 2010, Clinical colorectal cancer.

[87]  Wei Zhang,et al.  Positive KL-6 mucin expression combined with decreased membranous beta-catenin expression indicates worse prognosis in colorectal carcinoma. , 2008, Oncology reports.

[88]  M. Makuuchi,et al.  Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues. , 2007, Hepato-gastroenterology.

[89]  F. dall’Olio,et al.  Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948. , 2006, Glycobiology.

[90]  T. Irimura,et al.  Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma , 2004, Clinical & Experimental Metastasis.

[91]  K. Arisawa,et al.  Evaluation of sialyl Lewis(a), sialyl Lewis(x), and sialyl Tn antigens expression levels as predictors of recurrence after curative surgery in node-negative colorectal cancer patients. , 2002, Journal of experimental & clinical cancer research : CR.

[92]  K. Matsumoto,et al.  Genomic structure and transcriptional regulation of human Galbeta1,3GalNAc alpha2,3-sialyltransferase (hST3Gal I) gene. , 2001, Glycobiology.

[93]  M. Kitajima,et al.  Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. , 1995, Cancer.

[94]  T. Irimura,et al.  Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells. , 1995, Experimental cell research.

[95]  R. Niemelä,et al.  Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. , 1995, International journal of cancer.

[96]  D. Hayes,et al.  Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. , 1989, Cancer communications.

[97]  W. Zimmermann,et al.  The carcinoembryonic antigen gene family: structure, expression and evolution. , 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[98]  N. Kodagoda Interstitial pneumonitis. , 1972, Ceylon Medical Journal.